2023-04-05 09:44:33 ET
A Boston-based %Biotech company is already having quite the day on Wednesday leading up to the opening bell after the company announced that it has been awarded the third year of a Fast-Track Small Business Innovation Research grant from the NIH to support the clinical evaluation of TTX-MC138, according to this morning’s press release.
Shares of %TransCodeTherapeutics (Nasdaq: ) were being aggressively bid up during Wednesday’s premarket, with traders currently willing to buy shares at $0.422/share (+27.65% implied open for sellers) at the time of writing. This should be an excited session for this micro cap!
TransCode Therapeutics Inc is an RNA %Oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.